Table II.

Clinicopathological features and details of gene mutations in PDAC.

Sample ID	A	G	FNA histology	CEA, ng/ml	CA19-9, IU/ml	Location in pancreas	Tumor size, mm	Stage (UICC)	KRAS mutation (NGS)	Amino acid substitution (NGS)	Amino acid substitution (TaqMan)	TP53 mutation (NGS)	Other mutations
1	78	F	AC	3.8	1	Ph	25	IV	+	G12V	G12V	+
2	67	M	AC	12.6	1,130	Pbt	64	IV	+	G12V	G12V	+	SMAD4
3	64	M	AC	7.8	504	Pb	53	IV	+	G12V	G12V	+
4	69	M	AC	10.1	70,890	Ph	34	IV	+	G12D	G12D	+
5	47	M	AC	2.4	105	Ph	25	IV	+	G12D	G12D	+
6	68	M	AC	20.2	150	Pbt	29	IV	+	G12D	G12D	+
7	77	F	AC	37.3	24,421	Pb	41	IV	+	G12V	G12V	+	CDKN2A
8	64	M	AC	151	1,039	Ph	51	IV	+	G12D	G12D	+
9	53	F	AT	37.4	1,064	Pbt	60	IV	+	G12D	G12D	−
10	73	M	AC	196.8	37,107	Ph	49	IV	+	G12D	G12D	−	SMAD4
11	67	M	AC	7.3	67	Ph	38	IV	+	G12R	G12R	−
12	41	M	AC	0.9	110	Pbt	29	IV	+	G12D	G12D	−	CDKN2A
13	73	M	AC	4	403	Pb	39	IV	+	G12D	G12D	−
14	74	M	AT	17.1	566	Ph	20	IV	+	G12D	G12D	−
15	74	M	AC	3.6	2,770	Ph	22	IV	−	−	−	−
16	49	M	AT	2.6	403	Pb	63	IV	+	G12D	G12D	−	CDKN2A
17	65	M	AT	3.7	630	Ph	26	III	+	G12D	G12D	+
18	75	F	AC	1.7	331	Pb	40	III	+	Q61H	−	−
19	66	M	AT	11.5	174	Pbt	64	III	+	G12R	G12R	−	SMAD4
20	79	M	AC	12.7	80	Pt	32	III	+	G12D	G12D	−
21	77	F	AT	2.1	24	Pbt	30	III	+	G12V	G12V	−
22	74	M	NM	62.5	1	Ph	35	III	+	G12D	G12D	−
23	84	F	SFAC	24	3	Pt	22	III	+	G12V	G12V	−
24	73	M	AC	2.6	38	Ph	20	IIA	+	G12D	G12D	+
25	86	F	AC	6.1	147	Pbt	32	IIA	+	G12R	G12R	+
26	84	M	AC	3.9	563	Ph	37	IIA	+	G12D	G12D	−	CDKN2A, MET, KIT
27	39	F	AC	1	46	Pb	16	IA	+	G12V	−	+

All patients had the same final diagnosis of pancreatic ductal adenocarcinoma. G, gender; A, age; M, male; F, female; FNA, fine-needle aspiration; CEA, Carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; UICC, Union for international cancer control; NGS, next generation sequencing; TP53, tumor protein 53; AC, adenocarcinoma; AT, atypical; SFAC, suspicious for adenocarcinoma; NM, no malignancy. Ph, pancreatic head; Pb, pancreatic body; Pt, pancreatic tail; Pbt, pancreatic body to tail.